1,734 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Buy
Article Searches
Intercept Reports Positive Top-Line Data for NASH, Shares Up http://www.zacks.com/stock/news/355517/intercept-reports-positive-top-line-data-for-nash-shares-up?cid=CS-ZC-FT-355517 Feb 20, 2019 - Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Why I Look For Dividend Growth, Not Just Dividend Safety https://seekingalpha.com/article/4242334-look-dividend-growth-just-dividend-safety?source=feed_all_articles Feb 20, 2019 - Growth trumps safety (longevity of raises) in my opinion.Lower current yield is quickly negated over time with high growth.FedEx is one such dividend growth and value play.
The Best Dividend Stocks For New Money Today https://seekingalpha.com/article/4242310-best-dividend-stocks-new-money-today?source=feed Feb 20, 2019 - The stock market is having a great start to the year with the S&P 500 up 11.0% YTD. Finding new companies to put new money to work is getting harder.No matter how high the market soars, something grea
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10. ... http://www.gurufocus.com/news/819032/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-109-million-of-shares Feb 19, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10.9 million of Shares, Stocks: MRK, release date:Feb 19, 2019
Affimed Lays Out Accelerated Pathway For AFM13 At R&D Day https://seekingalpha.com/article/4242225-affimed-lays-accelerated-pathway-afm13-r-and-d-day?source=feed_sector_healthcare Feb 19, 2019 - AFM13 data at ASH proved deepening and durable for relapsed & refractory Hodgkin's Lymphoma.Data compares favorably to existing salvage therapies and opens the door for accelerated approval.At a R&D d
Has AstraZeneca Returned To Growth? https://seekingalpha.com/article/4242188-astrazeneca-returned-growth?source=feed_sector_healthcare Feb 19, 2019 - Key brands exceeded sales estimates; Tagrisso and Lynparza are Standards of Care in their respective label indications.The company missed on EPS due to significant operating expenses.Return-to-growth
What Are The Highest Quality Dividend Growth Stocks? https://seekingalpha.com/article/4242014-highest-quality-dividend-growth-stocks?source=feed Feb 19, 2019 - Many dividend growth investors seek the highest-quality companies.Independent data providers such as S&P, Morningstar, and Simply Safe Dividends offer rankings of quality factors.A simple scoring syst
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193 Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Gilead Could Be The Winner From Washington State's Winner-Take-All Hep C Proposal https://seekingalpha.com/article/4241249-gilead-winner-washington-states-winner-take-hep-c-proposal?source=feed_sector_healthcare Feb 14, 2019 - Washington State wants to bring a Netflix model to Hepatitis C care on an RFP model winner-take-all basis.If cost is the major factor here, Gilead could win this contract.By itself, it wouldn't stem t
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853 Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.

Pages: 1234567...174

<Page 2>